X4 Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
32.7%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$9.6Mnext fiscal year
FY EPS (est.)
-$0.73next fiscal year
Monitoring Framework
Key Performance Indicators
U.S. XOLREMDI Product Revenue Quarterly2.5MTarget: Continued quarterly commercial growth in the U.S. market
4WARD Phase 3 Trial Enrollment Progress QuarterlyTarget: Complete enrollment of approximately 150 participants by the end of Q3 2026
Cash and Marketable Securities Balance Quarterly233.7MTarget: Maintain sufficient capital to fund operations through 2028
Watch Items
- 4WARD Phase 3 Trial Top-Line Data DisclosureTrigger: Release of top-line efficacy and safety data expected in the second half of 2026Action: Evaluate clinical efficacy (ANC response and annualized infection rate reduction) to support global regulatory filings in chronic neutropenia
- European Commercial Launch of XOLREMDITrigger: European Commission marketing authorization granted on April 29, 2026Action: Monitor commercial execution, pricing negotiations, and milestone payments under the Norgine partnership
- Operating Cash Burn RateTrigger: Post-restructuring R&D and G&A expenses of $15.5M and $7.0M in Q1 2026Action: Track cost-containment efficiency to ensure cash runway remains extended through 2028
Research as of 20 Jun 2026